How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

March 31, 2015

Combining Novel Agents for CLL

Dr. Jennifer R. Brown talks about combining novel agents for treating CLL as the next step to achieve longer remissions for patients. Until now, novel agents have only been used individually or in combination with antibodies. New studies are being designed to measure the efficacy of combining novel agents with [ Read More ]

December 18, 2018

Financial Constraints to Molecular Biomarker Testing

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.